Canada markets close in 37 minutes
  • S&P/TSX

    21,275.50
    -261.95 (-1.22%)
     
  • S&P 500

    4,585.53
    -77.32 (-1.66%)
     
  • DOW

    35,405.68
    -506.13 (-1.41%)
     
  • CAD/USD

    0.7993
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    85.91
    +2.09 (+2.49%)
     
  • BTC-CAD

    52,046.37
    -1,132.46 (-2.13%)
     
  • CMC Crypto 200

    991.70
    -17.69 (-1.75%)
     
  • GOLD FUTURES

    1,813.90
    -2.60 (-0.14%)
     
  • RUSSELL 2000

    2,117.18
    -45.27 (-2.09%)
     
  • 10-Yr Bond

    1.8650
    +0.0930 (+5.25%)
     
  • NASDAQ

    14,556.91
    -336.84 (-2.26%)
     
  • VOLATILITY

    22.09
    +2.90 (+15.11%)
     
  • FTSE

    7,563.55
    -47.68 (-0.63%)
     
  • NIKKEI 225

    28,257.25
    -76.27 (-0.27%)
     
  • CAD/EUR

    0.7053
    +0.0052 (+0.74%)
     

Global Glioblastoma Multiforme Treatment Markets Analysis & Forecasts, 2017-2020 & 2021-2028

·6 min read

Dublin, Dec. 01, 2021 (GLOBE NEWSWIRE) -- The "Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By End Use, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

The global glioblastoma multiforme treatment market size is expected to reach USD 4.2 billion by 2028 and is expected to expand at a CAGR of 8.8% from 2021 to 2028

The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy.

In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years.

Moreover, companies are collaborating to develop novel treatments. For instance, in October 2019, Advaxis, Inc., a clinical-stage biotechnology company, announced a research collaboration agreement with the University of California for the development and commercialization of novel immunotherapy by using the company's Lm Technology in mouse tumor models of glioblastoma multiforme. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme.

Existing companies are willing to acquire new companies with pipeline products to diversify their product portfolio. For instance, in May 2019, Merck announced the upfront USD 1.1 billion acquisition of Peloton Therapeutics, which grants it access to the PT2977 under trial glioblastoma drug. This acquisition is likely to strengthen its pipeline and improve its future revenue-generation ability.

Various initiatives undertaken by the governments and non-government bodies across the globe to increase awareness by educating people living with glioblastoma multiforme and raising funds for R&D activities and treatment are expected to fuel the glioblastoma multiforme (GBM) treatment market growth during the forecast period.

For instance, Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps in raising awareness about glioblastoma multiforme and motivating people to donate money for glioblastoma multiforme research activities.

Organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research.

The main aim of the campaign is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Moreover, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month.

Glioblastoma Multiforme Treatment Market Report Highlights

  • Based on treatment, in 2020, radiation therapy held the largest share owing to various benefits associated with it such as improved survival rate and effectiveness

  • By drug class, the others segment led the market in 2020 owing to the high number of prescriptions. The segment includes everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA)

  • The hospitals end-use segment dominated the market in 2020 and the trend is expected to continue during the forecast period. Hospitals are preferred by patients in terms of treatment accessibility and convenience

  • Asia Pacific is projected to witness the fastest growth during the forecast period owing to the presence of large unmet needs in the market and the growing awareness about glioblastoma multiforme

  • North America dominated the market in 2020 due to favorable reimbursement policies and the presence of major players in the region

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary
2.1 Market Outlook

Chapter 3 Glioblastoma Multiforme (GBM) Treatment Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing incidence of glioblastoma multiforme
3.3.1.2 Increasing approval for glioblastoma multiforme treatment
3.3.1.3 Increasing R&D activities
3.3.1.4 Rising awareness about glioblastoma multiforme
3.3.2 Market Restraint Analysis
3.3.2.1 Lack of effective therapies for glioblastoma multiforme
3.3.2.2 High cost of drug development and stringent regulations
3.4 Market Analysis Tools
3.4.1 Industry Analysis: Porter's
3.4.2 PESTLE Analysis
3.5 Regulatory & Reimbursement Scenario
3.5.1 Pipeline Analysis
3.5.2 Epidemiology Analysis by Region

Chapter 4 Glioblastoma Multiforme (GBM) Treatment Market: Segment Analysis, by Treatment, 2017 - 2028 (USD Million)
4.1 Definition and Scope
4.2 Treatment Market Share Analysis, 2020 & 2028
4.3 Segment Market Dashboard
4.4 Global Glioblastoma Multiforme Treatment Market, by treatment, 2017 to 2028
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
4.6 Surgery
4.7 Radiation Therapy
4.8 Chemotherapy
4.9 Targeted Therapy
4.10 Tumor Treating Fields Therapy
4.11 Immunotherapy

Chapter 5 Glioblastoma Multiforme (GBM) Treatment Market: Segment Analysis, by Drug Class, 2017 - 2028 (USD Million)
5.1 Definition and Scope
5.2 Drug Class Market Share Analysis, 2020 & 2028
5.3 Segment Market Dashboard
5.4 Global Glioblastoma Multiforme Treatment Market, by Drug Class, 2017 to 2028
5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
5.6 Temozolomide
5.7 Bevacizumab
5.8 Lomustine
5.9 Carmustine Wafers

Chapter 6 Glioblastoma Multiforme (GBM) Treatment Market: Segment Analysis, by End-Use, 2017 - 2028 (USD Million)
6.1 Definition and Scope
6.2 End-use Market Share Analysis, 2020 & 2028
6.3 Segment Market Dashboard
6.4 Global Glioblastoma Multiforme Treatment Market, by End-Use, 2017 to 2028
6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
6.6 Hospitals
6.7 Clinics
6.8 Ambulatory Surgical Centers

Chapter 7 Glioblastoma Multiforme (GBM) Treatment Market: Regional Market Analysis, 2017 - 2028 (USD Million)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2020 & 2028
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Market Size, & Forecasts, Trend Analysis, 2020 to 2028

Chapter 8 Glioblastoma Multiforme (GBM) Treatment Market: Competitive Analysis
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.2 Company Categorization
8.3 Vendor Landscape
8.4 Public Companies
8.5 Private Companies
8.6 Major Deals and Strategic Alliances Analysis
8.7 Company Profiles

  • Merck & Co., Inc.

  • Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

  • Teva Pharmaceutical Industries Ltd.

  • Sun Pharmaceutical Industries Ltd.

  • F. Hoffmann-La Roche Ltd.

  • Pfizer, Inc.

  • Amgen, Inc.

  • Arbor Pharmaceuticals, LLC

  • Amneal Pharmaceuticals

  • Karyopharm Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ioaxy0


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting